Make an impact in your community by donating or registering for Relay For Life.
Immunotherapy for oral cancer
Immunotherapy is sometimes used to treat oral cancer. Immunotherapy helps to strengthen or restore the immune system’s ability to fight cancer. Immunotherapy is sometimes called biological therapy.
You may have immunotherapy to treat recurrent or metastatic oral cancer if the cancer has stopped responding to chemotherapy with platinum drugs such as cisplatin or carboplatin.
The most common immunotherapy drug used to treat oral cancer is nivolumab (Opdivo). It is usually given in a vein in the arm (by IV) every 2 weeks.
Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of immunotherapy. You may also receive other treatments.
Side effects can happen with any type of treatment for oral cancer, but everyone’s experience is different. Some people have many side effects. Other people have few or none at all.
Side effects of immunotherapy will depend mainly on the type of drug or drug combination, the dose, how it’s given and your overall health. Nivolumab may cause these side effects:
Report side effects
Be sure to report side effects to the healthcare team. Side effects can happen any time during, immediately after or a few days or weeks after immunotherapy. Sometimes late side effects develop months or years later. Most side effects go away on their own or can be treated, but some side effects may last a long time or become permanent.
Your healthcare team is there to help. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.
Information about specific cancer drugs
Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.
Questions to ask about immunotherapy
Great progress has been made
Some cancers, such as thyroid and testicular, have survival rates of over 90%. Other cancers, such as pancreatic, brain and esophageal, continue to have very low survival rates.